Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug ESG406 enters human trials for Hard-to-Treat cancers

NCT ID NCT06979674

Recruiting now Disease control Sponsor: Shanghai Escugen Biotechnology Co., Ltd Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 31 times

Summary

This early-phase study tests a new drug called ESG406 in adults (ages 18-80) with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety and find the best dose. Researchers will also watch for any tumor shrinkage. The study is currently recruiting participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED/METASTATIC SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Chongqing University Cancer Hospital

    RECRUITING

    Chongqing, Chongqing Municipality, 400030, China

    Contact

  • The First Affiliated Hospital of Xi 'An Jiaotong University

    RECRUITING

    Xi’an, Shanxi, 710061, China

    Contact

  • The Second Affiliated Hospital, Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310009, China

    Contact

Conditions

Explore the condition pages connected to this study.

LOCALLY ADVANCED/METASTATIC SOLID TUMORS